肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

CLIN CANCER RES：TOP2A和EZH2早期诊断侵袭性前列腺癌

2017-11-29 MedSci MedSci原创

侵袭性前列腺癌TOP2AEzh2
关注

目前的临床参数不能区分出侵袭性前列腺癌。侵袭性前列腺癌是从局部肿瘤进展为远处转移的一种前列腺癌，与大部分前列腺癌相关死亡有关。最近的基因表达研究可以成功预测前列腺癌患者的结局。但是目前尚需能够阻止患者进展为转移性疾病的靶向治疗方法。CLIN CANCER RES近期发表了一篇文章，研究侵袭性前列腺癌的分子标志。

目前的临床参数不能区分出侵袭性前列腺癌。侵袭性前列腺癌是从局部肿瘤进展为远处转移的一种前列腺癌，与大部分前列腺癌相关死亡有关。最近的基因表达研究可以成功预测前列腺癌患者的结局。但是目前尚需能够阻止患者进展为转移性疾病的靶向治疗方法。CLIN CANCER RES近期发表了一篇文章，研究侵袭性前列腺癌的分子标志。

作者共研究了7个原发前列腺癌队列（n=1900），2个转移性去势抵抗前列腺癌数据库（n=293）和一个前瞻性队列（n=1385）评估TOP2A和EZH2表达对前列腺癌细胞和患者结局的影响。并对已知临床结局的原发前列腺癌患者（n=89）进行TOP2A和EZH2免疫组化染色。最后还使用前列腺癌细胞系研究靶向TOP2A和EZH2联合治疗的潜力。研究结果表明，通过对原发和转移性前列腺癌数据的基因表达分析，TOP2A和EZH2 mRNA和蛋白表达上调与侵袭性更强的原发和转移性前列腺癌有关。更重要的是TOP2A和EZH2是前列腺癌中关键的驱动基因，针对其进行联合靶向治疗具有重要意义。

文章最后认为，该研究数据支持进一步研究TOP2A和EZH2作为早期鉴别具有转移可能性的前列腺癌患者以及可能从靶向治疗中获益的患者的分子标志。

原始出处：
David P.Labbe,Christopher J.Sweeney,et al.TOP2A and EZH2 Provide Early Detection of an Aggressive Prostate Cancer Subgroup.CLIN CANCER RES.November 2017 doi:10.1158/1078-0432.CCR

本文系梅斯医学（MedSci）原创编译整理，转载需授权！

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1746904, encodeId=0d841e4690464, content=<a href='/topic/show?id=5fefe188e3' target=_blank style='color:#2F92EE;'>#Ezh2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7188, encryptionId=5fefe188e3, topicName=Ezh2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2a935872940, createdName=fusion, createdTime=Mon Jun 04 15:21:00 CST 2018, time=2018-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366284, encodeId=7841136628497, content=<a href='/topic/show?id=186126998e2' target=_blank style='color:#2F92EE;'>#侵袭性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26998, encryptionId=186126998e2, topicName=侵袭性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Fri Dec 01 00:21:00 CST 2017, time=2017-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1382676, encodeId=ce9413826e600, content=<a href='/topic/show?id=1f4e5946422' target=_blank style='color:#2F92EE;'>#早期诊断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59464, encryptionId=1f4e5946422, topicName=早期诊断)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Fri Dec 01 00:21:00 CST 2017, time=2017-12-01, status=1, ipAttribution=)]
    2018-06-04 fusion

    #Ezh2#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1746904, encodeId=0d841e4690464, content=<a href='/topic/show?id=5fefe188e3' target=_blank style='color:#2F92EE;'>#Ezh2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7188, encryptionId=5fefe188e3, topicName=Ezh2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2a935872940, createdName=fusion, createdTime=Mon Jun 04 15:21:00 CST 2018, time=2018-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366284, encodeId=7841136628497, content=<a href='/topic/show?id=186126998e2' target=_blank style='color:#2F92EE;'>#侵袭性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26998, encryptionId=186126998e2, topicName=侵袭性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Fri Dec 01 00:21:00 CST 2017, time=2017-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1382676, encodeId=ce9413826e600, content=<a href='/topic/show?id=1f4e5946422' target=_blank style='color:#2F92EE;'>#早期诊断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59464, encryptionId=1f4e5946422, topicName=早期诊断)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Fri Dec 01 00:21:00 CST 2017, time=2017-12-01, status=1, ipAttribution=)]
    2017-12-01 sunyl07

    #侵袭性#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1746904, encodeId=0d841e4690464, content=<a href='/topic/show?id=5fefe188e3' target=_blank style='color:#2F92EE;'>#Ezh2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7188, encryptionId=5fefe188e3, topicName=Ezh2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2a935872940, createdName=fusion, createdTime=Mon Jun 04 15:21:00 CST 2018, time=2018-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366284, encodeId=7841136628497, content=<a href='/topic/show?id=186126998e2' target=_blank style='color:#2F92EE;'>#侵袭性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26998, encryptionId=186126998e2, topicName=侵袭性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Fri Dec 01 00:21:00 CST 2017, time=2017-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1382676, encodeId=ce9413826e600, content=<a href='/topic/show?id=1f4e5946422' target=_blank style='color:#2F92EE;'>#早期诊断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59464, encryptionId=1f4e5946422, topicName=早期诊断)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Fri Dec 01 00:21:00 CST 2017, time=2017-12-01, status=1, ipAttribution=)]
    2017-12-01 一叶知秋

    #早期诊断#

    0